PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

October 30, 2025

Primary Completion Date

April 30, 2029

Study Completion Date

April 30, 2029

Conditions
Intrahepatic Cholangiocarcinoma (Icc)
Interventions
DRUG

CISGEM + Rilvegostomig

"Administration of 4 cycles pre-operative and 4 cycles post-operative of Cisplatine associated to Gemcitabine with rilvegostomig~RILVEGOSTOMIG : For each cycle one administration at D1 every 3 weeks~• 750 mg IV administration over 60 minutes (up to a total of 90 minutes). CISGEM: For each cycle administration at D1 and D8 every 3 weeks~* Cisplatine 25 mg/m² in 1 hour IV in 1000 ml NaCl 0,9 % then 500 ml NaCl 0,9 %~* Gemcitabine 1000 mg/m² en 30 mn IV dans 250 ml NaCl 0,9 %"

Trial Locations (9)

54500

Nancy Chru, Nancy

Unknown

Chu Caen Normandie, Caen

Centre Gf Leclerc, Dijon

Chu de Dijon, Dijon

Chu Grenoble Alpes, Grenoble

Chu Dupuytren, Limoges

Hopital de La Timone Ap-Hm, Marseille

Hopital Prive Du Confluent, Nantes

Chu de Poitiers, Poitiers

All Listed Sponsors
lead

Federation Francophone de Cancerologie Digestive

OTHER